ArticlePharmaceutics2020
In Vitro Evaluation of Antimicrobial Activity of Minocycline Formulations for Topical Application in Periodontal Therapy.
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Antibacterial Agent-Loaded, Novel In Situ Forming Implants Made with Poly(Isosorbide Sebacate) and Dimethyl Isosorbide as a Solvent for Periodontitis Treatment.Molecules (Basel, Switzerland) · 2025Article
- Effect of a bacterial glutaminyl cyclase inhibitor on multi-species-biofilms.Frontiers in oral health · 2025Article
- Preclinical Validation of MIN-T: A Novel Controlled-Released Formulation for the Adjunctive Local Application of Minocycline in Periodontitis.Antibiotics (Basel, Switzerland) · 2024Article
- What Are the Potential Benefits of Using Bacteriophages in Periodontal Therapy?Antibiotics (Basel, Switzerland) · 2022Review
- The Application of Antimicrobial Photodynamic Therapy (aPDT) in the Treatment of Peri-Implantitis.Computational and mathematical methods in medicine · 2022Review
- Classic vs. Novel Antibacterial Approaches for Eradicating Dental Biofilm as Adjunct to Periodontal Debridement: An Evidence-Based Overview.Antibiotics (Basel, Switzerland) · 2021Review
- Local Oral Delivery Agents with Anti-Biofilm Properties for the Treatment of Periodontitis and Peri-Implantitis. A Narrative Review.Molecules (Basel, Switzerland) · 2021Review
- Clindamycin as an Alternative Option in Optimizing Periodontal Therapy.Antibiotics (Basel, Switzerland) · 2021Review
- A Review of Systemic Minocycline Side Effects and Topical Minocycline as a Safer Alternative for Treating Acne and Rosacea.Antibiotics (Basel, Switzerland) · 2021Review
- Controlled Delivery Formulations.Pharmaceutics · 2021Article
- Dental Practice during COVID-19 in Nepal: A Descriptive Cross-sectional Study.JNMA; journal of the Nepal Medical Association · 2020Article
- Production and characteristics of a novel chicken egg yolk antibody (IgY) against periodontitis-associated pathogens.Journal of oral microbiology · 2020Article
- Analysis of the Antimicrobial, Cytotoxic, and Antioxidant Activities ofPlants (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Periodontal therapy using antimicrobials that are topically applied requires slow or controlled release devices. The in vitro antimicrobial activity of biodegradable polymer formulations that contain a new minocycline lipid complex (P-MLC) was evaluated. The new P-MLC formulations that contained 11.5% minocycline were compared with pure minocycline or an existing commercial formulation, which included determination of minimal inhibitory concentration (MIC) values against two oral bacteria and activity on six-species periodontal biofilm. Moreover, the flow of gingival crevicular fluid (GCF) was modeled up to 42 d and the obtained eluates were tested both for MIC values and inhibiting biofilm formation. In general, MICs of the P-MLC formulations were slightly increased as compared with pure minocycline. Biofilm formation was clearly inhibited by all tested formulations containing minocycline with no clear difference between them. In 3.5 d old biofilms, all formulations with 250 µg/mL minocycline decreased bacterial counts by 3 log10 and metabolic activity with no difference to pure antimicrobials. Eluates of experimental formulations showed superiority in antimicrobial activity. Eluates of one experimental formulation (P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.